ArticleJournal for immunotherapy of cancer2026

Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.

Zhe Fu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.